EcoDrugPlus

Tgf-Beta Receptor Type-1-Like

Ensembl ID : ENSOMEG00000009621
Gene Symbol: LOC112139043
3 Cross references
204 Possible Orthologues:

Ttk Protein Kinase

Ensembl ID : ENSOMEG00000005039
Gene Symbol: TTK
3 Cross references
204 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSOMEG00000005427
Gene Symbol: UGCG
1 Cross references
211 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSOMEG00000002981
Gene Symbol: WEE1
3 Cross references
205 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSOMEG00000003245
Gene Symbol: YES1
4 Cross references
208 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSOMEG00000003023
Gene Symbol: ACHE
3 Cross references
231 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSOMEG00000000787
Gene Symbol: ACVR2B
3 Cross references
195 Possible Orthologues:

Activin A Receptor Type 2ba

Ensembl ID : ENSOMEG00000001302
Gene Symbol: ACVR2BA
1 Cross references
193 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSOMEG00000005546
Gene Symbol: ADORA1
4 Cross references
204 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSOMEG00000008375
Gene Symbol: ADORA2A
3 Cross references
197 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSOMEG00000010566
Gene Symbol: ADORA2B
1 Cross references
199 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSOMEG00000015079
Gene Symbol: ADA
3 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).